Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNMAu8 at the 2023 American Academy of Neurology Annual Meeting Clene NASDAQCLNN

SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. CLNN (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced three presentations at the upcoming 2023 American Academy of Neurology (AAN)…Read More